FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUVmax as a predictive biomarker in frontline treatment of mantle cell lymphoma

David A. Russler-Germain; Brendan R. Calhoun; Ningying Wu; Marcus P. Watkins; Barry A. Siegel; Nancy L. Bartlett; Joyce C. Mhlanga

doi:10.1080/10428194.2023.2239404

FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUV_max as a predictive biomarker in frontline treatment of mantle cell lymphoma

David A. Russler-Germain, Brendan R. Calhoun, Ningying Wu, Marcus P. Watkins, Barry A. Siegel, Nancy L. Bartlett, Joyce C. Mhlanga

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	1870-1874
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	64
Issue number	11
DOIs	https://doi.org/10.1080/10428194.2023.2239404
State	Published - 2023

Access to Document

10.1080/10428194.2023.2239404

Cite this

Russler-Germain, D. A., Calhoun, B. R., Wu, N., Watkins, M. P., Siegel, B. A., Bartlett, N. L., & Mhlanga, J. C. (2023). FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUV_max as a predictive biomarker in frontline treatment of mantle cell lymphoma. Leukemia and Lymphoma, 64(11), 1870-1874. https://doi.org/10.1080/10428194.2023.2239404

@article{2e953783823948cea663f958d734d0ad,

title = "FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUVmax as a predictive biomarker in frontline treatment of mantle cell lymphoma",

author = "Russler-Germain, {David A.} and Calhoun, {Brendan R.} and Ningying Wu and Watkins, {Marcus P.} and Siegel, {Barry A.} and Bartlett, {Nancy L.} and Mhlanga, {Joyce C.}",

note = "Funding Information: NLB receives research funding from Autolus, Celgene/Bristol Myers-Squibb, Forty-Seven, Janssen, Kite/Gilead, Merck, Millennium, and Pharmacyclics, and serves as a consultant/advisor for ADC Therapeutics, Genentech/Roche, and Seattle Genetics. BAS serves as a consultant for Curium Pharma, Lantheus Medical, Capella Imaging, and GE Healthcare.",

year = "2023",

doi = "10.1080/10428194.2023.2239404",

language = "English",

volume = "64",

pages = "1870--1874",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "11",

}

TY - JOUR

T1 - FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUVmax as a predictive biomarker in frontline treatment of mantle cell lymphoma

AU - Russler-Germain, David A.

AU - Calhoun, Brendan R.

AU - Wu, Ningying

AU - Watkins, Marcus P.

AU - Siegel, Barry A.

AU - Bartlett, Nancy L.

AU - Mhlanga, Joyce C.

N1 - Funding Information: NLB receives research funding from Autolus, Celgene/Bristol Myers-Squibb, Forty-Seven, Janssen, Kite/Gilead, Merck, Millennium, and Pharmacyclics, and serves as a consultant/advisor for ADC Therapeutics, Genentech/Roche, and Seattle Genetics. BAS serves as a consultant for Curium Pharma, Lantheus Medical, Capella Imaging, and GE Healthcare.

PY - 2023

Y1 - 2023

UR - http://www.scopus.com/inward/record.url?scp=85165687630&partnerID=8YFLogxK

U2 - 10.1080/10428194.2023.2239404

DO - 10.1080/10428194.2023.2239404

M3 - Letter

C2 - 37489928

AN - SCOPUS:85165687630

SN - 1042-8194

VL - 64

SP - 1870

EP - 1874

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 11

ER -

FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUVmax as a predictive biomarker in frontline treatment of mantle cell lymphoma

Access to Document

Other files and links

Cite this

FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUV_max as a predictive biomarker in frontline treatment of mantle cell lymphoma